Compare Cytokinetics Inc (CYTK) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Vanguard Growth Index Fund ETF — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while Vanguard Growth Index Fund ETF trades at $87.25. Which is the better fit depends on your goals.
| CYTK | VUG | |
|---|---|---|
Market Cap | $11.12B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $87.26 | $90.29 |
52-Week Low | $33.23 | $70.00 |
Enterprise Value | $11.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
VUG trades at $86.15, down 1.43% on the day, with a neutral technical signal and bullish moving averages. Recent news highlights its low 0.03% expense ratio and 411% total return over the past decade. The ETF is heavily concentrated in technology stocks (70% of assets) and executed a 1:6 stock split in April 2026.
Outlook remains positive for long-term growth investors given strong historical performance and cost efficiency, though high tech exposure and market volatility present risks. The fund's ability to adapt to economic growth trends supports its appeal, but investors should weigh concentration risk against diversification benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
